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Strengths and limitations of this study
 ► The case study design allowed for an in- depth ex-
ploration of the development and implementation of 
a regional policy for standardising labelling of pa-
tient lines and tubes.
 ► We were able to recruit a mixture of policy- makers 
and frontline staff which allowed us to understand 
a range of different experiences of the design and 
implementation of the regional line- labelling policy.
 ► We were not able to interview as many people as 
originally planned, and the geographical spread of 
those interviewed was uneven.
 ► The study used interviews and documentary analy-
sis; direct observations were not possible.
AbStrACt
Objective To identify and learn from efforts to design and 
implement a standardised policy for labelling of invasive 
tubing and lines across a regional health system.
Design Single case study involving qualitative interviews 
and documentary analysis.
Setting A devolved health system in the UK National 
Health Service (NHS).
Participants NHS staff (n=10) and policy- makers (n=8) 
who were involved in the design and/or implementation of 
the standardised policy.
results Though standardising labelling of invasive tubing 
and lines was initially seen as a common- sense technical 
change, challenges during the process of developing and 
implementing the policy were multiple and sociotechnical 
in nature. Major challenges related to defining the 
problem and the solution, limited sustained engagement 
with stakeholders and users, prototyping/piloting of the 
solution, and planning for implementation. Some frontline 
staff remained unconvinced of the need for or value of 
the policy, since they either did not believe that there was 
a problem or did not agree that standardised labelling 
was the right solution. Mundane practical issues such 
authorisation and resourcing, supply chains for labels, the 
need to restructure work practices to accommodate the 
new standard, and the physical features of the labels in 
specific clinical settings all had important impacts.
Conclusions Newly standardised tools and practices have 
to fit within a system of pre- existing norms, practices and 
procedures. We identified a number of practical, social 
and cultural challenges when designing and implementing 
a standardised policy in a regional healthcare system. 
Taking account of both sociocultural and technical aspects 
of standardisation, combined with systems thinking, 
could lead to more effective implementation and increase 
acceptability and usability of new standards.
IntrODuCtIOn
Standardisation is often considered as an 
intuitively obvious solution to some types of 
challenges facing the quality and safety of 
healthcare.1 Broadly defined, standards are 
specifications of rules, guidelines or charac-
teristics for designing products or carrying 
out activities.2 Standardisation has a prom-
ising role in reducing error,3–5 removing 
unnecessary variation4 6 and reducing uncer-
tainty in clinical interactions.7 Despite the 
increasing penetration of guidelines and 
other forms of standardised practices into 
healthcare, many everyday objects, patient 
pathways, workflows and tools of work 
remain highly localised and variable from 
setting to setting.8 Sometimes this variability 
is appropriate; sometimes, however, it intro-
duces risks and inefficiencies that would be 
best addressed through standardisation or 
harmonisation. One example was the entropy 
of crash call numbers across the National 
Health Service (NHS) which persisted 
until the introduction of the standard 2222 
number in 2004.9 However, standardisation 
is rarely a straightforward process: challenges 
may arise, for example, because standards 
themselves are defined and implemented 
through complex sociotechnical processes 
involving people, routines, protocols and 
technologies, requiring multiple kinds of 
purposeful effort during development, 
implementation and maintenance stages.10 
Understanding the existing system into which 
standards are to be introduced or refined is 
crucial for their success (ie, for their uptake 
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by stakeholders).11 Yet the challenges associated with 
standardisation of everyday objects have remained largely 
neglected as a focus of study.
In this article, we report a qualitative case study of the 
development and implementation of a line- labelling policy 
that sought to standardise labelling of invasive tubing and 
lines across a single devolved regional health system in 
the UK. Invasive tubes and lines (which we will refer to 
collectively as ‘lines’) are used for multiple purposes in 
patient care, including patient monitoring, administra-
tion of fluids, medication or feeding, and drainage of 
bodily fluids. Though ubiquitous in healthcare, lines are 
associated with significant safety challenges, including 
those relating to wrong route and wrong site error and 
infection12 13 and the risks may be increased when a large 
number of lines are positioned in close proximity to 
one another or when patients move from one service to 
another.14 Consistent labelling of lines is considered good 
practice and, in principle, has potential to mitigate some 
of these problems.15–17 Some countries, such as Australia, 
have issued a national policy to standardise labelling of 
lines and injectable medicines,18 but, notwithstanding 
some guidance from the now- defunct National Patient 
Safety Agency,19 the UK has not done so.
It is important that attempts to standardise cumulate 
learning. We aimed to examine a recent policy effort to 
design and implement a standardised line- labelling policy 
in one of the four devolved nations of the UK, with the 
aim of learning from the experience and informing prac-
tical ways to improve similar efforts in the future.
MethODS
We conducted a single case study20 of the development 
and implementation of a line- labelling policy in one of 
the four nations of the UK with a devolved health system. 
The case study design allowed for an in- depth exploration 
of the project and its context, based on interviews with a 
range of clinical and non- clinical staff in local trusts (NHS 
organisations) and documentary analysis. The organisa-
tions and individuals participating in the case study are 
anonymised.
Primary data came from semi- structured telephone 
interviews with NHS staff and policy makers, conducted 
between February and September 2017, following the 
introduction of the line- labelling policy in January 2017. 
Key staff members were identified by the project lead for 
the regional line- labelling policy, and those staff were 
contacted through the chief medical officer’s (CMO’s) 
office with an invitation to take part in an interview, an 
information sheet explaining the nature of the study and 
information to allow them to respond direct to the study 
team. In total, 64 staff members were invited. The study 
team received 27 responses from interested participants. 
Due to scheduling difficulties and some lack of response 
to follow- up contact, we completed 18 interviews. Inter-
views were audio recorded after obtaining written consent 
and transcribed verbatim.
In addition to the interviews, we analysed documentary 
sources related to the line- labelling policy which were 
provided to the study team by the project lead and dated 
from 1998 onwards. These sources comprised minutes of 
meetings that discussed reviews of line labelling policies 
from one trust; minutes of meetings from the Regional 
Policy Group discussing development of plans for region- 
wide standardisation; presentations to staff about prac-
tices of line labelling; a copy of the letter from the CMO to 
staff about introducing the new policy; previous local line- 
labelling policies dating from 1998 and 2008 from one 
trust; and the text of the new regional policy, including 
a poster presenting the label designs. These documents 
helped the study team to understand the history of the 
policy’s development which is outlined in the first section 
of the Results.
Both interview transcripts and documentary data anal-
ysis was based on the constant comparative method,21 
and NVivo (QSR V.11) was used in order to organise 
and manage data and coding effectively. The analysis was 
concurrent with data collection and was carried out by 
NMK. Coding was largely inductive, but was also informed 
by sensitising concepts from the quality improvement and 
organisational change literature. Codes were then organ-
ised into four global themes, reflecting key dimensions 
of the process of developing and implementing a new 
standard: operational and organisational considerations, 
adaptive considerations, technical considerations and 
implementation considerations.
Patient and public involvement
This was a study of a policy targeting staff behaviours and 
organisational systems. Patients and the public were not 
involved in this study.
Data availability
The consent for this project restricts use of the transcripts 
to the study team. Requests to access anonymised data 
should be made to the corresponding author; further 
ethical and governance approvals may be required to 
enable sharing.
reSultS
Of the 18 individuals interviewed, 10 were policy- makers 
(eg, civil servants) who were part of a working group 
charged with designing and overseeing the implemen-
tation of the policy. Eight were NHS frontline staff who 
were involved in implementing the policy across three 
trusts (healthcare organisations).
We offer, first, a descriptive summary of the histor-
ical development of the devolved region’s standardised 
line- labelling policy using primarily documentary 
sources, before highlighting key challenges during the 
process of designing and implementing region- wide 
standardisation.
Developing and implementing the policy
Some of the origins of the policy lay partly in one of 
the trusts in the region, which had, in 1998, developed 
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its own local line- labelling policy. It provided guidance 
aimed at ensuring that invasive lines could be traced 
to their source and were labelled appropriately, using 
nine types of standardised labels. After a merger, the 
policy was updated in 2008 and extended to 11 types of 
labels. An audit in the trust in April 2011 demonstrated 
poor compliance with the 2008 policy. Staff reported 
that they could not locate the specific labels required 
by the policy, and that multiple different labels were 
available for the same line. It also became apparent that 
line- labelling practices—for example, whether lines 
were labelled at all, and how they were labelled—varied 
across the trust. These variations were seen by trust 
management as concerning.
An audit took place in Paediatrics; the objective be-
ing to ensure the policy is being adhered to and to 
improve compliance if appropriate, the overall re-
sult was very poor as they were unable to obtain the 
coloured labels stated in the policy. (Minutes from 
Standards and Guidelines Committee Meeting in one 
trust, April 2011)
The trust brought these concerns to the Regional 
Policy Group Collaborative (RPGC), a committee estab-
lished in 2010 to coordinate the production of clinical 
policy across the health system. At a meeting of the RPGC 
in December 2011, it was identified that these concerns 
were likely to be evidence of a more generalised problem, 
and it was agreed that a region- wide line- labelling policy 
should be developed and implemented.
 [Two trusts] reported that there are few national stan-
dards [for line labelling]. Agreement from group that 
we should make an effort to deliver a regional policy. 
(Minutes from RPGC meeting, December 2011)
In March 2012, a working group comprising repre-
sentatives from both the RPGC and each trust in the 
health system was established to oversee the development 
of the new policy, with two project leads. The working 
group completed a scoping exercise to understand what 
line- labelling policies and label designs were already in 
use in different trusts. It then produced a first draft of 
the line- labelling policy and submitted it to the RPGC 
for comment. In December 2012, the working group 
received some initial feedback about amending the title 
of the policy and the need for all labels to be coloured. 
At the following RPGC meeting in March 2013, members 
agreed that the policy’s scope should be widened to 
include all possible lines, not just invasive lines (as had 
been the case in previous trust- level policies), and that 
each label should have its own colour code.
[Project lead] to amend and widen the scope of the 
policy.
The Collaborative agreed the list should include as 
many tubes/lines as possible and assign and [a] co-
lour [to] each.
(Minutes from RPGC meeting, March 2013)
The working group consulted with frontline staff across 
the health system (senior doctors, nursing leads and 
other senior staff) via email to get their feedback on the 
policy, with the aim of achieving consensus on the designs 
for the labels (colours, fonts and additional identifying 
features such as borders), and on the design for a poster 
for use in the clinical settings where staff would be using 
the labels.
Each representative on the Collaborative will email 
MDs/Nursing Leads and Senior Staff to agree co-
lour before ordering. (Minutes from RPGC meeting, 
March 2013)
The feedback was incorporated into the final policy, which 
had 21 different types of labels. In addition to setting out a 
colour code for each line and a standard catalogue of label 
designs, the policy also sought to standardise practices asso-
ciated with line- labelling, requiring that all lines be labelled 
and that all staff (with the explicit exception of ambulance 
staff) label lines. The primary purpose expressed in the 
policy document was ‘to safeguard the patient and health 
care professional by reducing ‘wrong route administration’ 
area of risk and to avoid confusion where invasive lines and 
tubes are in situ’ (Policy for the identification and labelling 
of invasive lines and tubes, January 2017).
It is unclear exactly when the final draft of the policy 
was agreed, in part because the RPGC was dissolved at 
some point during the policy’s final development stages. 
“Months, maybe a year, or more” (participant 16, working 
group) passed between the moment when the final draft 
policy was agreed by the working group and the policy was 
adopted by senior policy- makers.
During 2016, the health system’s CMO agreed that the 
policy should be adopted. In November 2016, the CMO 
and the chief nursing officer (CNO) sent a joint letter to all 
trusts informing them that the policy would be introduced 
in early January 2017. All trusts were expected to implement 
the policy at the same time. They were asked to remove old 
labels from their stores and to ensure that they had ordered 
enough new labels to arrive in time for the proposed date. 
However, the start date had to be pushed back until the end 
of January 2017, following problems obtaining a financial 
contribution from each trust to cover the cost of printing 
plates for the new labels. The CMO and CNO then issued a 
second joint letter notifying trusts of the new date of imple-
mentation once the issue had been resolved.
There is no phased introduction of the policy—all parts 
of every organisation are expected to comply from 9 
January. Please ensure that any previous drafts of the pol-
icy are removed and replaced with the version included 
with this letter. (Extract from joint letter from CMO and 
CNO, November 2016)
Challenges encountered
Four major challenges were encountered, relating to 
defining the problem, limited sustained engagement with 
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stakeholders and users, prototyping/piloting of the solu-
tion and planning for implementation.
Defining the problem and the solution
There was reasonable consensus among participants that 
the main aim of the region- wide line- labelling policy was 
to improve patient safety by reducing the risk of wrong 
route administration occurring, that is, “To help them 
[staff] not to do the wrong thing” (participant 4, working 
group).
…the aim of the line- labelling programme, as far as 
I can see, was to make sure that, number one, that 
there was standardisation across the region, so that 
when nurses and doctors move between hospitals, 
the colours and the design of the labels is the same, 
so you’re less likely to…have harm or error done. 
(Participant 11, working group)
As one member of the working group put it, standard-
ising line- labelling was seen as “a no- brainer” (partici-
pant 7). Some members of the working group felt that 
the need to standardise line- labelling in order to prevent 
wrong route administration was so obvious that they did 
not need to convince frontline staff of this.
I suspect we didn't really need to persuade people 
that it was a patient safety issue. It was a fairly obvious 
one. (Participant 2, working group)
But, from the beginning, the working group seemed to 
focus on the solution (standardising line- labelling across 
the region) rather than on the actual problem (wrong 
route administration). Though the working group had 
some anecdotal evidence on the incidence of wrong 
route administration, no quantified baseline data were 
available, nor was evidence explicitly linking the problem 
to inadequate line- labelling.
One of the things that we didn’t have any baseline 
for…was any incidents to quantify the risks of it not 
being standardised. I suppose it seemed to be more 
of a sense that this was the right thing to do rather 
than any evidence that people had come to harm be-
cause it wasn’t done. (Participant 5, working group)
Staff at the sharp end of care did not universally share 
the view that there was in fact a problem or that the stand-
ardisation policy was the solution.
I am a little unclear…as to exactly what the aim and 
benefit of the line- labelling programme is. …I sup-
pose I don't really feel anybody has necessarily ever 
explained the need, the need for the policy…I don't 
think anybody has really made the case for the need 
for change. (Participant 12, frontline)
Staff at the sharp end raised several concerns about the 
effectiveness of labels in preventing wrong route admin-
istration from happening. For example, the same inter-
viewee felt that “it's a partial system, in that, if someone 
is going to put the wrong substance into the wrong line, 
having a sticker on it, it doesn't force them in any way”. 
A senior nurse was “not convinced that a label actually 
reduces harm to patients” (participant 6, frontline). A 
nurse from a dialysis unit recalled an incident where a 
doctor misused a dialysis catheter, but where a label would 
not have helped matters:
…to have a label on that dialysis catheter would not 
have prevented that doctor from doing what he did…
He knew it was a dialysis catheter, but he just decid-
ed that he couldn’t get peripheral access and that he 
would go ahead and that he would use this for blood 
and that he would deliver the antibiotics down it, he 
didn’t use (antiseptic technique) and he didn’t flush 
it properly and it clotted. But a label wouldn’t have 
prevented that. …he already knew it was dialysis, the 
patient told them, this is my dialysis line, this is my 
dialysis catheter. (Participant 17, frontline)
Limited sustained engagement with stakeholders and users
The members of the working group involved in the design 
and development stages gave a generally positive account 
of the consultation with staff. They emphasised that 
representatives for frontline staff in different trusts and 
professional groups had helped to develop the policy as 
part of the working group, and other staff were consulted 
about the label designs.
It's not like something that’s been put upon them 
with no consultation, you know, this has never been 
put upon anybody, everybody had the opportunity to 
consult. …we got lots of comments back and we took 
some of them on board and others we sort of put a 
line through them. But I think that’s why it's going to 
work because we touched so many stakeholders in-
volved and so many people consulted. (Participant 1, 
working group)
It’s about ensuring that they’re involved from the 
very start. So they were the key people round the ta-
ble, the staff who would actually have to take it back 
to their organisation and say, this is what we want to 
do. (Participant 8, working group)
However, frontline staff perceived things somewhat 
differently, reporting that when they were emailed for 
their feedback on the policy, they were sent a copy of the 
poster that set out the label designs and were asked for 
their comments on it. They reported that they did not 
have a say on the problem to be addressed or on the solu-
tion set out in the policy, only on the details of its imple-
mentation. Some staff we interviewed at the sharp end 
were sceptical about the consultation process as a result, 
complaining, for example, about short turnaround times.
I received [the poster with label designs] 1 day and a 
few days later, it almost had to be back within two or 
3 days, so I didn’t follow that up physically. I didn’t 
walk around everywhere asking people to look at 
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it, and so I got no comments back. (Participant 14, 
frontline)
Another saw the consultation as more informational 
than consultative.
It didn’t come as a finished product but you didn’t 
have input either. It was very much that this was a 
work in progress and that there were people from 
every trust meeting regionally to discuss, and that 
they would then be implementing it. (Participant 17, 
frontline)
Prototyping/piloting of the solution
The working group thought the policy was too straight-
forward to justify experimentation with designs and phys-
ical examples of the labels, especially as it had assumed 
that all staff were already labelling all lines, although 
inconsistently.
This was merely a state of change and once we’d 
agreed the labels it was just a case of swapping them 
over. (Participant 5, working group)
The absence of prototyping and piloting meant that 
practical issues with the policy emerged only after imple-
mentation. Many of these issues related primarily to the 
label designs. For instance, one participant pointed out 
that the same colour label was used for two different lines, 
and that the colours chosen for some labels did not match 
existing colouring systems used for identifying devices or 
injectable medications for specific lines, suggesting that 
the scoping exercise and consultation with staff on the 
label designs had not been sufficiently comprehensive.
I just know with the epidural labels, in the epidur-
al policy that we have for the trust, everything’s sup-
posed to be yellow but not only does it [the new 
epidural label] match the colour for the pulmonary 
artery flotation catheter, it’s not actually yellow, it’s 
not what staff would expect either, it’s like…a yellowy 
green colour, and then the enteral tube labels are 
supposed to be purple, so it’s not just that they match 
or are similar to other labels on the chart, but they’re 
not the colour that they should be in the first place. 
(Participant 14, frontline)
The same participant also commented that the new 
labels were “not of the same quality and they just look 
more shabby” than labels they had used previously. These 
apparently lower quality labels required changing more 
frequently, but were also stickier, which caused problems 
when changing labels on paediatric patients, particularly 
neonates. The size of the labels also caused problems in 
both paediatric and adult wards.
…the size of the labels themselves, they're large, and 
I have had a number of emails…around the size of 
the labels and how that’s interfering sometimes 
with…one of them was a patient’s NG [nasogastric] 
tube. The size of the label meant that it was obscuring 
the vision of the patient because of…the position of 
the label that’s required in the policy. (Participant 6, 
frontline)
Additionally, line- labelling was a new practice in some 
specialties, contrary to the working group’s assump-
tion that all staff were already labelling lines. In dialysis, 
for example, lines were not regularly labelled, as staff 
reported that dialysis lines were designed for a specific 
purpose and could not be confused for anything else (as 
noted in the example above with the doctor who misused 
a dialysis catheter), so labelling them was unnecessary 
work for staff.
…we feel it’s kind of one policy fits all and it really 
doesn’t fit with us for a number of reasons. We’re la-
belling lines that we know exactly what they are; ev-
ery single person who’s working in that unit knows 
what dialysis lines are. (…) People are mentored for 
6 weeks and trained how to put these lines on – you 
cannot mistake these lines for anything else, they are 
dialysis machine lines, they won’t fit anything else, 
there’s slots on them that will only fit into a machine 
(…) [I]t’s a nonsense for something that has no val-
ue, whether you write catheter, whether you write 
line, everybody knows these are dialysis lines. There’s 
no value whatsoever, and it’s just adding work for peo-
ple. (Participant 17, frontline)
Planning for implementation
Obtaining appropriate sign- off for the policy before 
implementation proved challenging. The dissolution of 
the RPGC meant that the working group struggled to 
identify how to get the policy approved.
…we had [the RPGC], and that would have, probably, 
been the place that things like this would have been 
signed off, and that group ceased to exist…there 
were delays in trying to get…what would replace that, 
what’s the mechanism for getting regional sign off, 
so things, kind of, went quiet for a while. (Participant 
16, working group)
In one trust, the policy was only formally signed off in 
December 2017 to be implemented from January 2018, 
when the initial objective was to implement in January 
2017.
Sites followed instructions to remove old labels ahead 
of the regional implementation date in January 2017, 
but issues with printing and distributing the labels led to 
delays. A small amount of funding was needed to create 
the new printing plates, but this turned out to be difficult 
to source from each of the trusts, delaying the project.
We did get into a ludicrous situation at one point…
we needed a small amount of money, it was less £1000 
and trying to find less than £1000 to buy your first 
batch of labels was horrendously difficult. (Participant 
5, working group)
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Further, the number of labels needed for the first order 
was underestimated. While these problems were dealt with 
relatively quickly, not all sites that were due to implement 
the policy had received their labels on the new start date.
Well, when they [the labels] initially came here there 
was a problem in stock…the first week we started we 
were on the back foot and told that we really didn’t 
have the supply of labels that we probably would 
need. But we’ve eventually sorted that and it’s not a 
problem now, but they just hadn’t really anticipated 
the demand that we would require, so that was a bit 
disappointing that someone hadn’t thought that one 
through really. (Participant 3, frontline)
Issues with the supply chain of labels from the printer 
to the wards lasted for at least 6 months in some sites. 
Although one of the working group leads stated in 
February 2017 that “the issue has now been resolved” 
(participant 1, working group), one hospital nurse, inter-
viewed in June 2017, had still not received all the labels 
for their department.
The working group expected managers to be key 
stakeholders of the policy and support implementation. 
However, not all managers were behind the policy, and 
not all ensured that the policy was implemented in their 
organisation or that staff seeking to implement the policy 
were adequately supported.
Well, the chief medical officer gave a presentation…
and it was clear that [organisations within] the trust 
were not all implementing the labels, some I think 
hadn’t…so he did emphasise the need for medical di-
rectors in the trust to take ownership of this and make 
sure it all gets implemented properly. (Participant 15, 
working group)
I think support from senior level in the trust would 
be helpful because now that people have reported 
concerns to me I need to reassure them that not only 
have I passed that on, but that actions are going to 
be taken or whatever, so that’s important for people 
at clinical level to get that feedback. (Participant 14, 
frontline)
The working group planned that an initial audit, led 
by a regional quality improvement authority, should take 
place three to 6 months after the initial start date to evaluate 
the implementation of the policy, focusing mainly on staff 
compliance. Although reducing wrong route administra-
tion was the primary purpose of the policy, the impact of 
the policy could not be assessed as no baseline data on this 
issue were collected before the policy was implemented.
DISCuSSIOn
This study has identified that many of challenges faced 
throughout developing and implementing a standardised 
line- labelling policy across a single devolved health system 
were practical and logistical in nature, while others were 
more social and cultural in character. These findings 
have broader relevance for large- scale standardisation 
exercises.
Convincing people that there is a problem, and that the 
proposed solution is appropriate, are known challenges 
in healthcare improvement.22 This project ran into chal-
lenges relating to problem definition23: the working group 
believed the problem and the solution they proposed 
were obvious and compelling, but this view was not 
shared across all levels of the system. The lack of baseline 
data to support the project in the first place seemed to be 
a key driver here; indeed, recent research suggests that 
line- labelling discrepancies may not be strongly related to 
medical errors or harm.13 The project also encountered 
challenges relating to consensus on the chosen solution. 
The line- labelling policy was framed as a common- sense 
technical change, but this did not account for those areas 
that would need to restructure their work to accommo-
date the new standard,1 24 particularly those who felt that 
the requirement to label all lines was in conflict with their 
perception that some lines did not need to be labelled. 
Providing a coherent programme theory for the inter-
vention25 26 that identified the goals and the mechanisms 
of change25 27 might have helped staff to better under-
stand the rationale behind the policy. Spending time on 
problem exploration and definition leads to better solu-
tion design,28 29 and this is important when creating a case 
for change to convince others that there is a problem that 
needs to be worked on.
Further challenges arose relating to design problems 
that surfaced only after implementation. Important 
strategies for optimising and implementing design- 
based solutions include prototyping (circulating physical 
exemplars, ie, the new labels) and piloting (testing the 
proposed policy in a defined perimeter). These activ-
ities support communication with stakeholders, aid in 
learning and inform decision- making about prospective 
designs.30 Prototyping, testing and evaluating solutions 
in short refinement cycles are core aspects of a design 
thinking approach.31 32 When confronting potential users 
with prospective designs, they should be presented with 
an artefact with which they can interact, and observe how 
they do it—for example, through clinical simulation.33 34 
Observation is important because participants may esti-
mate one solution to be better in a survey, when actual 
experimentation shows otherwise.35 However, proto-
typing and piloting was very limited in the line- labelling 
project. One problem was that the new colour code for 
labels in some cases conflicted with established stan-
dards that appeared to be effective, pointing to the more 
general problem that standardisation that involves de- im-
plementation of existing practices is often a fraught and 
delicate challenge.36
Finally, mundane supply chain issues such as capacity 
at the printing company and availability of budgets for 
printing plates compounded the challenges, affecting 
simultaneous implementation of the policy across the 
region. Anticipating needs and ensuring sufficient avail-
ability of labels before setting an implementation date 
7Kriznik NM, et al. BMJ Open 2019;9:e031771. doi:10.1136/bmjopen-2019-031771
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would have helped to prevent these delays. Models, such 
as process models or project management models, can 
be helpful to plan the various phases of projects and to 
design implementation processes.37 38
In terms of informing future practices, these findings 
illustrate general learning relevant for efforts to stan-
dardise in healthcare. In particular, emphasising that new 
standards are not implemented in a vacuum; they always 
have to fit into an ecology of pre- existing systems, norms, 
behaviours and established practices.10 Standardisation is 
often considered as a neutral exercise, yet it may privi-
lege the views of particular groups and alter how people 
work together in a sociomaterial world.24 Understanding 
the underlying nature of these pre- existing elements 
before designing, let alone implementing, standards 
is crucial to ensure that standardisation is not seen as a 
merely technocratic process, but rather as one that takes 
into consideration the potential impact on working 
routines and relationships and recognises the political 
nature of standardisation.1 24 This ecology affects the 
whole life cycle of any standard, from its inception to its 
deployment. All stages involve a network of stakeholders, 
specific constraints and distinct challenges. Delivering on 
operational reality for standardisation projects requires 
creating shared vision and understanding, strong coor-
dination and project management to secure progress, 
and a ‘design thinking’ spirit with attention to multiple 
mundane details to deliver practical, usable standards. 
Relevant and ongoing communications with key stake-
holders should be seen as good practice when developing 
standards. This also includes the need for appropriate 
testing or simulation of standards before they are imple-
mented on a larger scale, particularly when changing or 
introducing the use of technologies or other physical 
artefacts in healthcare settings. This allows for adequate 
reflection on the proposed standards, including both 
physical designs and also the rationale for standardisation.
This study provided a useful case study from which to 
draw lessons for future large- scale standardisation proj-
ects. We were able to interview a broad range of stake-
holders, though not as many people as originally planned, 
and the geographical spread of those interviewed was 
uneven. Further, the study was retrospective, based on 
interviews and documents, aiming to explore staff expe-
riences of the design and implementation of the policy. 
Consequently, it was not possible to observe meetings or 
to collect data on the impact of the line- labelling project 
on compliance or outcomes.
COnCluSIOnS
In this case study of the development and implemen-
tation of a standardised line- labelling policy in one of 
the devolved regional healthcare systems in the UK, 
what appeared to be a viewed as a ‘common- sense’ 
response to a perceived problem did not fully take 
into account the wider system, including established 
norms, practices and existing standards. Consequently, 
not all staff were convinced of the need for this policy 
or of its proposed efficacy. These findings suggest that 
improving understanding of the underlying theoretical 
and philosophical aspects of standardisation, coupled 
with the introduction and use of ‘design thinking’ tech-
niques, would improve future large- scale standardisa-
tion processes in healthcare.
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